Skip to content

Physiological Effects of Nitrous Oxide on Anaesthesia

Nitrous Oxide and Inhalational Agent Pharmacokinetics During Anaesthetic Induction and Emergence

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01092923
Enrollment
20
Registered
2010-03-25
Start date
2009-10-31
Completion date
2010-10-31
Last updated
2012-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Keywords

Nitrous Oxide, washin, washout, second gas effect, sevoflurane, induction, emergence

Brief summary

Nitrous oxide is the oldest anaesthetic agent still in routine use today. Despite huge changes in the pharmacology of volatile anaesthetic agents and intravenous anaesthetics, the unique properties of nitrous oxide have maintained its place in modern practice, where it is used in combination with other, more powerful inhaled agents, such as sevoflurane. It has useful analgesic properties, unlike the other agents used today, and its inclusion reduces the concentration of other agents required to maintain an adequate depth of anaesthesia for surgery. In particular, its low solubility in body tissues gives it a unique pharmacokinetic profile, with rapid washin and washout from the body. It has been shown to have a similar effect on the speed of uptake of accompanying agents like sevoflurane (the second gas effect), which have much slower pharmacokinetics. A recent study by us suggested that this promotes faster and smoother onset of anaesthesia, as measured using the standard monitor of depth of anaesthesia (the BIS monitor). This finding requires confirmation prospectively in a larger group of patients. The investigators further hypothesise that a similar effect also exists on washout of sevoflurane at the end of the procedure, promoting quicker recovery (emergence) from anaesthesia. This has never been previously demonstrated. This information will help better define the place of nitrous oxide in achieving optimal outcomes in modern anaesthetic practice. The investigators propose to conduct a simple study to measure the effects of nitrous oxide washin and washout on exhaled concentrations of accompanying sevoflurane during both induction of anaesthesia and emergence, and identify any accompanying effect on the rate of change in depth of anaesthesia using BIS. The investigators hypothesise that the rate of fall of exhaled sevoflurane concentration at the end of anaesthesia will be more rapid in the group of patients breathing a gas mixture containing nitrous oxide, and that the rate of fall of BIS on induction and the rate of rise of BIS on emergence will be faster in the nitrous oxide group.

Detailed description

Nitrous oxide is the oldest anaesthetic agent still in routine use today. Despite huge changes in the pharmacology of volatile anaesthetic agents and intravenous anaesthetics, the unique properties of nitrous oxide have maintained its place in modern practice, where it is used in combination with other, more powerful inhaled agents, such as sevoflurane. It has useful analgesic properties, unlike the other agents used today, and its inclusion reduces the concentration of other agents required to maintain an adequate depth of anaesthesia for surgery. In particular, its low solubility in body tissues gives it a unique pharmacokinetic profile, with rapid washin and washout from the body. It has been shown to have a similar effect on the speed of uptake of accompanying agents like sevoflurane (the second gas effect), which have much slower pharmacokinetics. A recent study by us suggested that this promotes faster and smoother onset of anaesthesia, as measured using the standard monitor of depth of anaesthesia (the BIS monitor). This finding requires confirmation prospectively in a larger group of patients. We further hypothesise that a similar effect also exists on washout of sevoflurane at the end of the procedure, promoting quicker recovery (emergence) from anaesthesia. This has never been previously demonstrated. This information will help better define the place of nitrous oxide in achieving optimal outcomes in modern anaesthetic practice. We propose to conduct a simple study to measure the effects of nitrous oxide washin and washout on exhaled concentrations of accompanying sevoflurane during both induction of anaesthesia and emergence, and identify any accompanying effect on the rate of change in depth of anaesthesia using BIS. Consenting adult participants will be recruited who are undergoing general anaesthesia for elective surgery anticipated to take a minimum of 1 hour and where an arterial line is considered appropriate for monitoring of blood pressure. As, in normal practice, the decision whether to include of nitrous oxide in the anaesthetic mixture is largely discretionary on the part of the anaesthetist, and therefore allocation to either arm of the protocol is consistent with routine practice, it is intended that the patients will be approached for consent on admission to hospital for their surgery. Standard patient monitoring will be used including BIS and a 2 mL sample of blood will be taken to assess blood gas content lung function and optimise lung ventilation. Following induction of anaesthesia, participants will receive an inhaled gas mixture containing standard concentrations of sevoflurane. They will be randomised to a treatment group where a standard concentration of nitrous oxide is included in this mixture, or a control group where nitrous oxide is not included. Monitoring and recording of exhaled gas concentrations will be made by continuous sampling of gas from the breathing circuit and computer storage. We hypothesise that the rate of fall of exhaled sevoflurane concentration at the end of anaesthesia will be more rapid in the group of patients breathing a gas mixture containing nitrous oxide, and that the rate of fall of BIS on induction and the rate of rise of BIS on emergence will be faster in the nitrous oxide group.

Interventions

DRUGsevoflurane on air/O2

sevoflurane on air/O2

DRUGsevoflurane in N2O/O2

sevoflurane in N2O/O2

Sponsors

Austin Health
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients undergoing elective general or orthopaedic surgery under relaxant general anaesthesia anticipated to take \>1 hour

Exclusion criteria

* Age under 18 years * Morbid obesity BMI \> 35 * Severe or moderately severe lung disease (FEV1 \< 1.0L, FEV1/FVC \< 50%) * Past history of severe post-operative nausea and vomiting * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)Baseline, 2 minutes, 5 minutes, and 30 minutes after emergenceRate of fall in the arterial partial pressure of sevoflurane relative to baseline at 2 minutes (Pa 2/Pa0 Sevo), 5 minutes (Pa 5/Pa0 Sevo, and 30 minutes (Pa 30/Pa0 Sevo)
PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)Baseline, 2 minutes, and 5 minutes after emergenceRate of fall in the end-tidal partial pressure of sevoflurane relative to baseline at 2 minutes (PA2/PA0 sevo) and 5 minutes (PA5/PA0 sevo)

Secondary

MeasureTime frameDescription
Time to Eye Opening20 MinutesThe time to eye opening to command after cessation of inhalational anaesthetic administration

Countries

Australia

Participant flow

Recruitment details

Dates of recruitment: December 2009 to April 2010 Location: Austin Health

Pre-assignment details

Exclusion criteria: patients with history of severe lung disease (defined as FEV1\<1.5 L or FEV1/FVC\<50%), symptomatic ischemic heart disease, super obesity (BMI\>45), pregnancy, prior severe post-operative nausea/vomiting, critically ill/immunocompromised, Vitamin B12/folate deficiency, or presence of any gas-filled, space-occupying lesion.

Participants by arm

ArmCount
Air/Oxygen
Sevoflurane with Air/Oxygen Mix
10
Sevoflurane in N2O/O2
Sevoflurane in 2:1 N2O/O2
10
Total20

Baseline characteristics

CharacteristicSevoflurane in N2O/O2Air/OxygenTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
5 Participants7 Participants12 Participants
Age, Categorical
Between 18 and 65 years
5 Participants3 Participants8 Participants
Age Continuous67 years
STANDARD_DEVIATION 13
65 years
STANDARD_DEVIATION 18
66 years
STANDARD_DEVIATION 16
Region of Enrollment
Australia
10 participants10 participants20 participants
Sex: Female, Male
Female
6 Participants5 Participants11 Participants
Sex: Female, Male
Male
4 Participants5 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)

Rate of fall in the arterial partial pressure of sevoflurane relative to baseline at 2 minutes (Pa 2/Pa0 Sevo), 5 minutes (Pa 5/Pa0 Sevo, and 30 minutes (Pa 30/Pa0 Sevo)

Time frame: Baseline, 2 minutes, 5 minutes, and 30 minutes after emergence

Population: based on data collected during previous pilot study investigating the magnitude of the second gas effect on sevoflurane partial pressures after anaesthesia induction, we expected an effect of roughly similar magnitude would be present during elimination of nitrous oxide.

ArmMeasureGroupValue (MEAN)Dispersion
Sevoflurane in N2O/O2Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)At 2 minutes0.32 ratioStandard Deviation 0.08
Sevoflurane in N2O/O2Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)At 5 minutes0.23 ratioStandard Deviation 0.07
Sevoflurane in N2O/O2Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)At 30 minutes0.16 ratioStandard Deviation 0.08
Sevoflurane in Air/O2Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)At 2 minutes0.44 ratioStandard Deviation 0.13
Sevoflurane in Air/O2Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)At 5 minutes0.32 ratioStandard Deviation 0.06
Sevoflurane in Air/O2Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)At 30 minutes0.20 ratioStandard Deviation 0.1
Primary

PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)

Rate of fall in the end-tidal partial pressure of sevoflurane relative to baseline at 2 minutes (PA2/PA0 sevo) and 5 minutes (PA5/PA0 sevo)

Time frame: Baseline, 2 minutes, and 5 minutes after emergence

Population: based on data collected during previous pilot study investigating the magnitude of the second gas effect on sevoflurane partial pressures after anaesthesia induction, we expected an effect of roughly similar magnitude would be present during elimination of nitrous oxide.

ArmMeasureGroupValue (MEAN)Dispersion
Sevoflurane in N2O/O2PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)At 5 minutes0.14 ratioStandard Deviation 0.02
Sevoflurane in N2O/O2PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)At 2 minutes0.18 ratioStandard Deviation 0.04
Sevoflurane in Air/O2PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)At 5 minutes0.17 ratioStandard Deviation 0.06
Sevoflurane in Air/O2PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)At 2 minutes0.22 ratioStandard Deviation 0.07
Secondary

Time to Eye Opening

The time to eye opening to command after cessation of inhalational anaesthetic administration

Time frame: 20 Minutes

ArmMeasureValue (MEAN)Dispersion
Sevoflurane in N2O/O2Time to Eye Opening8.7 MinutesStandard Deviation 1.3
Sevoflurane in Air/O2Time to Eye Opening11.0 MinutesStandard Deviation 1.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026